Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
1 clinical trials · Condition
◉ Watch Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) (NCT02900664) | Novartis Pharmaceuticals | 2016-08-23 |
Track Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.